Elanco Animal Health Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
ELAN$26.76-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash Flows from Operating Activities | ||
| Net income (loss) | $346 | $(1,090) |
| Adjustments to reconcile net income (loss) to cash flows from operating activities: | ||
| Depreciation and amortization | 498 | 523 |
| Goodwill impairment | — | 1,042 |
| Stock-based compensation expense | 40 | 31 |
| Asset impairment and write-down charges | 76 | 5 |
| Gain on divestiture | (640) | — |
| Proceeds from interest rate swap settlements | 5 | 57 |
| Changes in operating assets and liabilities, net of acquisitions and divestitures | 93 | (446) |
| Other non-cash operating activities, net | (54) | (8) |
| Net Cash Provided by Operating Activities | 364 | 114 |
| Cash Flows from Investing Activities | ||
| Net purchases of property and equipment and software | (100) | (99) |
| Cash paid for acquisitions | (5) | (19) |
| Proceeds from business divestitures | 1,294 | — |
| Proceeds from previous sale of Shawnee and Speke facilities (see Note 4) | 66 | — |
| Purchases of intangible assets | (8) | (14) |
| Other investing activities, net | 1 | (2) |
| Net Cash Provided by (Used for) Investing Activities | 1,248 | (134) |
| Cash Flows from Financing Activities | ||
| Proceeds from Revolving Credit Facility | 50 | 350 |
| Repayments of Revolving Credit Facility | (250) | (53) |
| Proceeds from Securitization Facility | 170 | 250 |
| Repayments of Securitization Facility | (170) | (97) |
| Proceeds from issuance of long-term debt | 350 | — |
| Repayments of long-term borrowings | (1,587) | (388) |
| Other financing activities, net | (23) | (6) |
| Net Cash (Used for) Provided by Financing Activities | (1,460) | 56 |
| Effect of exchange rate changes on cash and cash equivalents | (14) | (12) |
| Net increase in cash and cash equivalents | 138 | 24 |
| Cash and cash equivalents – beginning of period | 352 | 345 |
| Cash and cash equivalents – end of period | $490 | $369 |
2024 Q3 Form 10-Q | 8
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.